Maggie McCloskey, Lung Cancer Patient Advocate, shared a post on LinkedIn:
“All biomarker tests are NOT created equal! Make sure you are ordering comprehensive testing that includes testing for DNA, RNA and Protein for your NSCLC patients.
This is a great article from American Society of Clinical Oncology (ASCO) that explains the importance of comprehensive testing and compares testing products.”
Svetlana Nikic, Founder of Precision Oncology Consulting, shared this post, adding:
“What means a negative result of a CGP? Well, the answer is ‘it depends’.
Great commentary on challenges related with comprehensive genomic profiling assays highlighting an urgent need to define a common ground and a minimum set of requirements for a CGP assay to be truely comprehensive and clincialy actionnable.
Not all CGP Assays are developed in a same way and not all findings are interpretef/reported in a same way – importantly, that impacts patient management and their outcomes.
Harmonisation on what CGP is, is urgently needed.”
Title: Illusion of Comprehensive Testing in Non–Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter
Authors: Teja Voruganti, Xiaoke Wang, Christiana Davis, Anthony O. Martella, Melina E. Marmarelis, Charu Aggarwal
Read the Full Article.
Other articles featuring Svetlana Nikic on OncoDaily.